Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.10 USD
0.00 (0.00%)
Updated Oct 4, 2024 04:00 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Theravance Biopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 102 | 327 | 173 | 293 | 281 |
Receivables | 17 | 17 | 14 | 16 | 22 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 14 | 9 | 62 | 85 | 36 |
Total Current Assets | 134 | 353 | 250 | 393 | 338 |
Net Property & Equipment | 9 | 12 | 14 | 16 | 13 |
Investments & Advances | 0 | 0 | 68 | 13 | 5 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 203 | 202 | 4 | 3 | 6 |
Total Assets | 382 | 607 | 375 | 469 | 409 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 3 | 7 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 17 | 19 | 10 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 20 | 38 | 76 | 58 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 0 | 0 | 12 | 32 |
Total Current Liabilities | 25 | 29 | 59 | 124 | 112 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 7 |
Convertible Debt | 0 | 0 | 228 | 227 | 226 |
Long-Term Debt | 0 | 0 | 371 | 373 | 219 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 99 | 91 | 2 | 2 | 21 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 169 | 166 | 713 | 773 | 633 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,122 | 1,296 | 1,387 | 1,223 | 1,025 |
Retained Earnings | -909 | -854 | -1,726 | -1,527 | -1,249 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 213 | 442 | -339 | -304 | -224 |
Total Liabilities & Shareholder's Equity | 382 | 607 | 375 | 469 | 409 |
Total Common Equity | 213 | 442 | -339 | -304 | -224 |
Shares Outstanding | 49.80 | 67.30 | 73.70 | 63.90 | 56.70 |
Book Value Per Share | 4.28 | 6.56 | -4.59 | -4.75 | -3.95 |
Fiscal Year End for Theravance Biopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 96 | 100 | 102 | 134 |
Receivables | NA | 14 | 15 | 17 | 17 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 9 | 10 | 14 | 11 |
Total Current Assets | NA | 119 | 124 | 134 | 162 |
Net Property & Equipment | NA | 8 | 9 | 9 | 9 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 203 | 203 | 203 | 205 |
Total Assets | NA | 362 | 371 | 382 | 414 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 11 | 9 | 13 | 13 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 6 | 6 | 6 | 0 |
Total Current Liabilities | NA | 23 | 22 | 25 | 25 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 101 | 99 | 101 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 168 | 166 | 169 | 167 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,131 | 1,126 | 1,122 | 1,147 |
Retained Earnings | NA | -937 | -921 | -909 | -901 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 194 | 205 | 213 | 246 |
Total Liabilities & Shareholder's Equity | NA | 362 | 371 | 382 | 414 |
Total Common Equity | 0 | 194 | 205 | 213 | 246 |
Shares Outstanding | 48.90 | 48.60 | 48.50 | 49.80 | 52.80 |
Book Value Per Share | 0.00 | 3.99 | 4.22 | 4.28 | 4.66 |